Amgen, AstraZeneca Say Tezspire Showed Improvement in Eosinophilic Esophagitis in Phase 3 Study

09:40 AM EDT, 10/20/2026 (MT Newswires) -- Amgen (AMGN) and AstraZeneca (AZN) said Tuesday that Tezspire showed "statistically significant and clinically meaningful" improvements in patients with symptomatic and uncontrolled eosinophilic esophagitis, as per results from the phase 3 Crossing trial. The study showed that treatment with Terzspire achieved histologic remission for 64.8% for the 210mg dose and 68.9% for the 420mg dose of patients at week 24, compared with 3.5% of patients on placebo, according to a statement. Tezspire further demonstrated a reduction in frequency and severity of dysphagia symptoms by 18.8 points for the 210 mg dose and 22 points for the 420 mg dose versus 14.7 points on placebo, the companies said. The results were sustained through week 52, the companies added. Shares of Amgen and AstraZeneca rose more than 1% and 2%, respectively, during early trading activity Tuesday. Price: 429.16, Change: +4.22, Percent Change: +0.99